Canna~Fangled Abstracts

The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.

By September 29, 2015No Comments
 2015;231:95-128.

Abstract

PM 1aThe endocannabinoids anandamide and 2-arachidonoylglycerol are metabolised by both hydrolytic enzymes (primarily fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL)) and oxygenating enzymes (e.g. cyclooxygenase-2, COX-2). In the present article, the in vivo data for compounds inhibiting endocannabinoid metabolism have been reviewed, focussing on inflammation and pain. Potential reasons for the failure of an FAAH inhibitor in a clinical trial in patients with osteoarthritic pain are discussed. It is concluded that there is a continued potential for compounds inhibiting endocannabinoid metabolism in terms of drug development, but that it is wise not to be unrealistic in terms of expectations of success.

KEYWORDS:

2-Arachidonoylglycerol; Anandamide; Cyclooxygenase-2; Drug development; Fatty acid amide hydrolase; Monoacylglycerol lipase; Pain

PMID:

 

26408159

 

[PubMed – as supplied by publisher]

LinkOut – more resources

Full Text Sources

  • Icon for Springer

twin memes II